09:28 AM EDT, 08/28/2025 (MT Newswires) -- Telomir Pharmaceuticals ( TELO ) said Thursday that recent in vitro data showed that its lead drug candidate Telomir-1 has the potential to help the human body reawaken its natural defenses against disease and decline.

In studies conducted by Eurofins Discovery, the drug was shown to potently inhibit UTX, an enzyme that influences stem cell renewal, reprogramming, and differentiation, and influence DNA methylation, Telomir said.

The new in vitro data strengthened Telomir-1's emerging profile as a broad epigenetic reset therapy that may help reawaken tumor suppressor genes, block cancer's growth enablers, and dial down inflammation, the company said.

The company's shares were up 30% in recent Thursday premarket activity.